Background/Aim. Local ablative treatments foroligo-progressive, EGFR mutated non-small cell lung cancer(mut-NCSLC) may improve long-term disease control andsurvival. We analyzed the efficacy of hypo-fractionated, highdose radiation therapy (HDRT), in association with prolongedEGFR tyrosine kinase inhibitors (TKI) in oligo-progressive,EGFR mutant-NSCLC. Patients and Methods. Progressionfree survival-1 (PFS-1, date from initiation of TKI therapyuntil oligo-progression or death), and progression-freesurvival-2 (PFS-2, date of focal progression until furtherprogression or death) were evaluated. Results. Thirty-sixpatients were analyzed. The median PFS 1 was 12.5 months.HDHRT consisted of intensity-modulated RT and stereotacticRT in 23 (64%) and 13 (36%) patients respectively. Themedian PFS 2 was 6.3 months. Overall survival was 38.7months. Conclusion. Hypo-fractionated HDRT plus TKItherapy, is associated with a significant prolongation ofdisease control (overall PFS: 18.8 months), with manageableside effects. These real-world data support the use of localablative approaches in oligo-progressive EGFR mut-NSCLC.
|Numero di pagine||6|
|Stato di pubblicazione||Published - 2020|